文献速递前列腺癌

高危和/或局部晚期前列腺癌手术联合或不联合达罗他胺:SUGAR(CCAFU-PR2)2期试验原理与方案

Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
PubMed 文献 · Eur Urol Oncol · 2023-10-06

SUGAR是首个2期、随机、对照、多中心、非商业、开放标签研究,计划随机分配240例非转移性高危前列腺癌男性,比较围手术期达罗他胺单药与直接根治性前列腺切除术的疗效与安全性。主要终点为不可治愈复发无生存,次要终点包括安全性、无复发生存、无转移生存、总生存、病理反应和生活质量,并进行预测性生物标志物分析。

要点

  • SUGAR试验针对国际泌尿病理学会分级分组≥4、磁共振成像精囊侵犯和/或临床淋巴结阳性的非转移性前列腺癌男性。
  • 试验组接受新辅助达罗他胺单药、根治性前列腺切除术及辅助达罗他胺,总治疗9个月。
  • 主要终点为不可治愈复发无生存,同时评估安全性、生存终点、病理反应、生活质量及预测性生物标志物。

核心结论

  • SUGAR将提供围手术期达罗他胺单药与直接根治性前列腺切除术相比,在当代高危前列腺癌手术人群中的疗效和安全性信息。

研究设计与样本

  • SUGAR是首个2期、随机、对照、多中心、非商业、开放标签研究,计划随机分配240例非转移性前列腺癌男性。
  • 主要入组标准为国际泌尿病理学会分级分组≥4、磁共振成像精囊侵犯和/或临床淋巴结阳性疾病。
  • 试验组接受新辅助达罗他胺单药、根治性前列腺切除术及辅助达罗他胺,完成9个月治疗。

主要发现

  • 初步数据提示,使用雄激素受体信号抑制剂(ARSI)的强化新辅助治疗与持续的病理反应相关,并可能通过肿瘤降期和微转移灶清除改善结局。
  • ARSI单药可能进一步提高耐受性。

关键数值与推荐

  • 主要终点为不可治愈复发无生存。
  • 次要终点包括安全性、无复发生存、无转移生存、总生存、病理反应和生活质量。
  • 将进行预测性生物标志物分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-risk prostate cancer (PCa) patients frequently experience recurrence and progression after radical prostatectomy (RP). Neoadjuvant androgen deprivation therapy (ADT) has not demonstrated a clear oncological benefit and is not currently recommended. OBJECTIVE: The SUGAR trial is the first phase 2, randomised, controlled, multicentre, noncommercial, open-label study investigating single-agent perioperative darolutamide compared with the standard of care (ie, upfront RP, without neoadjuvant ADT). DESIGN, SETTING, AND PARTICIPANTS: SUGAR aims to randomise 240 men affected by nonmetastatic PCa, with the major eligibility criteria being International Society of Urological Pathology grade group ≥4, seminal vesicle invasion at magnetic resonance imaging and/or clinically node-positive disease. Patients in the experimental arm will undergo neoadjuvant darolutamide monotherapy, RP, and adjuvant darolutamide, completing 9 mo of treatment. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint is noncurable recurrence-free survival, an innovative and clinically meaningful measure; the secondary endpoints encompass safety; recurrence-free, metastasis-free, and overall survival; pathological response; and quality of life. A predictive biomarker analysis will also be performed. RESULTS AND LIMITATIONS: Initial data suggest that intensified neoadjuvant treatment with androgen receptor signalling inhibitors (ARSIs) is associated with a sustained pathological response and may improve outcomes, via tumour downstaging and micrometastasis eradication. ARSI monotherapy could further enhance tolerability. CONCLUSIONS: SUGAR will provide efficacy and safety information on perioperative darolutamide monotherapy compared with upfront RP, in a contemporary high-risk PCa population undergoing surgery. PATIENT SUMMARY: The on-going SUGAR clinical trial evaluates 9 mo of darolutamide treatment in addition to radical prostatectomy, in men affected by prostate cancer with specific high-risk characteristics. It investigates whether this hormonal treatment can lower the rates of noncurable recurrences, maintaining a favourable tolerability profile.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Calleris G, Filleron T, Kesch C, et al. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol. Eur Urol Oncol. 2023. PMID: 37806843. doi:10.1016/j.euo.2023.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。